Browse the evidence

The extra amount of protein led to minor changes in body composition but not physical performance or muscle quality.

Practitioners should manage expectations regarding the impact of increased protein on physical performance and muscle quality.

No significant association was found between dietary carbohydrate and CVD mortality (HR=1.02; 95% CI: 0.91, 1.14).

Dietary carbohydrate intake may not significantly impact CVD mortality, suggesting other factors may be more influential.

Obesity prevalence is projected to grow by 40% in the next decade.

Healthcare practitioners should prepare for increased obesity-related health issues.

FIM programs often prioritize health equity.

Health care providers should ensure that FIM interventions are designed to promote health equity.

The use of mixed methods does not reach acceptable accuracy for 1RM prediction on an individual basis.

Practitioners should be cautious when using mixed methods for individual 1RM predictions.

There are concerns regarding the long-term safety and efficacy of GLP-1 receptor agonists.

Practitioners should monitor patients closely for safety and efficacy when prescribing GLP-1 receptor agonists.

Obesity is a disorder of energy metabolism characterized by low usable energy (ATP) in the setting of elevated total energy.

Practitioners should consider the role of energy metabolism in obesity management.

Treatment response heterogeneity is an important area of research in personalized and precision medicine.

Researchers should focus on understanding individual responses to treatments in nutrition and obesity.

Financial incentives, environmental change strategies, and their combination were not significantly more effective than usual care.

Practitioners should consider that these interventions may not provide significant advantages over standard care.

There is a need to develop new cost-effective strategies for OSA management.

Practitioners should consider implementing innovative and cost-effective strategies for managing OSA.

Less than half of obese patients were considering weight loss in the coming month.

Practitioners should address motivation and readiness to change in obese CHD patients.

The safety profile of tirzepatide is consistent across all phase 3 trials.

Practitioners can expect a consistent safety profile when prescribing tirzepatide.

Effect sizes of GLP-1 receptor agonists in schizophrenia are mostly smaller than in the general population.

While GLP-1 receptor agonists can aid in weight loss, practitioners should manage expectations regarding the magnitude of effect in this population.

Future trials of GLP-1 receptor agonists could focus on dual or triple agonist agents.

Exploring dual or triple agonist therapies may enhance treatment options for weight management in schizophrenia.

The study could not establish statistical significance regarding the likelihood of delayed gastric emptying in patients on GLP-1R agonists.

Further research is needed to clarify the relationship between GLP-1R agonists and gastric emptying.

Recommendations for incorporating genetics and genomics into clinical decision-making for behavioral weight loss are outlined.

Practitioners can consider these recommendations to enhance behavioral weight loss interventions.

Lifestyle interventions and older antiobesity pharmacotherapies have been associated with less than 12% body weight reduction and no clear benefit to reduce MACE risk.

Practitioners should be aware that traditional weight loss methods may not significantly reduce cardiovascular risks.

Barriers to providing advice on specific dietary patterns for T2DM include safety and compliance challenges.

Dietitians should be aware of and address safety and compliance issues when advising patients.

Genetic predisposition to higher BMI does not predict weight regain after weight loss.

Genetic factors related to BMI may not be useful for predicting weight regain, focusing instead on abdominal obesity genetics.

Genetic effects on abdominal obesity may be more pronounced than those on general obesity during weight regain.

Understanding the differential impact of genetics on abdominal versus general obesity can inform targeted interventions.

Companies can profit from CCT programs by selling enrollment as self-commitment devices.

Businesses can leverage CCT programs as a market opportunity while promoting healthier behaviors.

There is a need for sport event organizers to question and challenge claims of health promotion.

Sport organizations should critically evaluate their health promotion strategies and claims.

An inverse relationship was found between the sitting height to total height ratio and the SDL:CDL strength ratio.

Individuals with longer torsos may benefit more from the SDL.

There is an urgent need to develop effective therapies for diabetes to reduce the risks of serious complications.

Healthcare systems should prioritize the development of new diabetes therapies.